Etavopivat is the first in a new class of drugs to successfully meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
TCL Industries Hosts 2026 Global Partners Conference, Unveiling its Latest Roadmap and Innovation Strategy Amid Strong Growth
Bloom Holding Introduces Next-Generation Digital Solutions to Elevate Broker, Owner, and Resident Experiences
Bloom Holding Introduces Next-Generation Digital Solutions to Elevate Broker, Owner, and Resident Experiences